Cambridge Investment Research Advisors
ONC

Cambridge Investment Research Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,815
Closed -$681K – 3904
2025
Q2 		$681K Buy
+2,815
New +$690K ﹤0.01% 2255

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambridge Investment Research Advisors's ONC Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 2,815 shares — an estimated $681K sold.

Cambridge Investment Research Advisors first reported a position in ONC in Q2 2025 and held it in 1 quarter. The position peaked at $681K in Q2 2025. 266 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,815 BeOne Medicines Ltd shares in Q3 2025, an estimated $681K.
  • Cambridge Investment Research Advisors first reported a position in BeOne Medicines Ltd in Q2 2025 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's BeOne Medicines Ltd position peaked at $681K in Q2 2025.
  • 266 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.